Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
June 01 2022 - 7:00AM
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical
stage cell therapy company developing therapies with the potential
to transform the standard of care in solid organ transplantation
and severe immune and blood disorders, today announced it will host
a conference call to discuss its presentations at the American
Transplant Congress (ATC) and provide a data update from its
ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant
(LDKT) recipients.
The conference call will be held on June 8, 2022 at 8:00 a.m.
ET. To access the conference call, the dial-in numbers are
1-855-605-1739 for domestic callers and 1-914-987-7955 for
international callers. The conference ID number for the live call
will be 9988627. A live webcast of the conference call will also be
available under "News & Events" in the Investors section of the
Company's website at www.talaristx.com.
About Talaris TherapeuticsTalaris Therapeutics,
Inc. is a late-clinical stage cell therapy company developing
therapies with the potential to transform the standard of care in
solid organ transplantation and severe immune and blood disorders.
Talaris maintains corporate offices in Boston, MA, its cell
processing facility in Louisville, KY, and additional research
operations in Houston, TX.
Media ContactLisa RaffenspergerTen Bridge
Communicationslisa@tenbridgecommunications.com(617)
903-8783
Investor ContactChris BrinzeyICR
Westwickechris.brinzey@westwicke.com(339)
970-2843
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Apr 2023 to Apr 2024